Callewaert B L, Willaert A, Kerstjens-Frederikse W S, De Backer J, Devriendt K, Albrecht B, Ramos-Arroyo M A, Doco-Fenzy M, Hennekam R C M, Pyeritz R E, Krogmann O N, Gillessen-kaesbach G, Wakeling E L, Nik-zainal S, Francannet C, Mauran P, Booth C, Barrow M, Dekens R, Loeys B L, Coucke P J, De Paepe A M
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Hum Mutat. 2008 Jan;29(1):150-8. doi: 10.1002/humu.20623.
Arterial tortuosity syndrome (ATS) is a rare autosomal recessive connective tissue disease, characterized by widespread arterial involvement with elongation, tortuosity, and aneurysms of the large and middle-sized arteries. Recently, SLC2A10 mutations were identified in this condition. This gene encodes the glucose transporter GLUT10 and was previously suggested as a candidate gene for diabetes mellitus type 2. A total of 12 newly identified ATS families with 16 affected individuals were clinically and molecularly characterized. In addition, extensive cardiovascular imaging and glucose tolerance tests were performed in both patients and heterozygous carriers. All 16 patients harbor biallelic SLC2A10 mutations of which nine are novel (six missense, three truncating mutations, including a large deletion). Haplotype analysis suggests founder effects for all five recurrent mutations. Remarkably, patients were significantly older than those previously reported in the literature (P=0.04). Only one affected relative died, most likely of an unrelated cause. Although the natural history of ATS in this series was less severe than previously reported, it does indicate a risk for ischemic events. Two patients initially presented with stroke, respectively at age 8 months and 23 years. Tortuosity of the aorta or large arteries was invariably present. Two adult probands (aged 23 and 35 years) had aortic root dilation, seven patients had localized arterial stenoses, and five had long stenotic stretches of the aorta. Heterozygous carriers did not show any vascular anomalies. Glucose metabolism was normal in six patients and eight heterozygous individuals of five families. As such, overt diabetes is not related to SLC2A10 mutations associated with ATS.
动脉迂曲综合征(ATS)是一种罕见的常染色体隐性结缔组织病,其特征为广泛的动脉受累,表现为大中型动脉伸长、迂曲和动脉瘤形成。最近,在这种疾病中发现了SLC2A10突变。该基因编码葡萄糖转运蛋白GLUT10,此前曾被认为是2型糖尿病的候选基因。对总共12个新发现的有16名受累个体的ATS家系进行了临床和分子特征分析。此外,对患者和杂合子携带者均进行了广泛的心血管成像和葡萄糖耐量测试。所有16例患者均携带双等位基因SLC2A10突变,其中9种为新突变(6种错义突变、3种截短突变,包括1种大片段缺失)。单倍型分析表明,所有5种复发性突变均存在奠基者效应。值得注意的是,这些患者的年龄明显大于文献中先前报道的患者(P = 0.04)。只有1名受累亲属死亡,最可能是死于无关原因。尽管该系列中ATS的自然病程不如先前报道的严重,但确实表明存在缺血性事件风险。2例患者最初分别在8个月和23岁时出现中风。主动脉或大动脉迂曲总是存在。2名成年先证者(年龄分别为23岁和35岁)有主动脉根部扩张,7例患者有局限性动脉狭窄,5例患者有主动脉长段狭窄。杂合子携带者未显示任何血管异常。5个家系中的6例患者和8名杂合子个体的葡萄糖代谢正常。因此,显性糖尿病与与ATS相关的SLC2A10突变无关。